In adults severe GH deficiency has been a registered indication for the use of GH replacement since 1996. The UK prescribing policy has focused on a single biological endpoint, quality of life, whilst other European countries have adopted a holistic approach. How did this come about, why does the UK differ from its European neighbours, and is the UK practice satisfactory from an Endocrinologist's perspective ?
Declaration of interest: There is no conflict of interest that could be perceived as prejudicing the impartiality of the research reported.
Funding: No specific grant from any funding agency in the public, commercial or not-for-profit sector.